What is a Breakthrough Therapy?
A new drug may be designated as a breakthrough therapy by the Food and Drug Administration (FDA) if it is intended to treat a serious or life-threatening disease and preliminary clinical evidence suggests it provides a substantial improvement over existing therapies. Once the breakthrough therapy designation is requested by the drug sponsor, the FDA and sponsor work together to determine the most efficient path forward.
Breakthrough Designations Announced By Companies (Updated 8/24/2015):
I saw the weather prediction segment the other day and again today. Many analysts continue to insist on predicting the future of the stock market with mixed results and now they are applying their unproven nonsense to the weather.
Some call for California to experience the 'most rain in a century'. In California during the Winter, rain usually means warm and no rain brings cold. I am always suspicious of the success of predictions whatever they may be, especially when extremes or sensationalism for the sake of personal notoriety, publicity or viewership ratings is placed in focus.
Having said that, my prediction for the West Coast is for a Winter that will be average, if there is such a thing, with rainfall in the lower part of the past decade recordings range, in the current trend called normal. People will use natural gas and propane to heat their homes and businesses in a usual and expected manner.
Weather will not effect the stock price of Magnum Hunter Resources in the near term.
As an investor with energy positions I would love to see the dawning of a new Ice Age that would slowly grind through New York and scrape away Wall Street, the New York Yankees and the Boston Red Sox. Uninterrupted delivery of Natural Gas on the East Coast during this time period that would make me filthy rich as people struggle to survive, would be my only concern.
Magnum Hunter Resources Corporation Analyst Rating Update
Money Flow Index
August 18, 2015
by Erick Mckenzie in Market Indices
Magnum Hunter Resources Corporation (NYSE:MHR) has received a short term rating of buy from research analysts at Zacks with a rank of 2. The company has been rated an average of 2.33 by 12 Wall Street Analysts. 4 analysts have added the shares in their list of strong buys. 2 stock experts have also rated a buy. 5 analysts have advised hold. 1 has rated the company as strong sell.
Many analysts have commented on the company rating. Equity Analysts at the KeyBanc maintains the rating on Magnum Hunter Resources Corporation (NYSE:MHR). The brokerage firm has issued a Overweight rating on the shares. The Analysts at the ratings agency lowers the price target from $3.5 per share to $2.5 per share. The rating by the firm was issued on July 14, 2015.
Magnum Hunter Resources Corporation (NYSE:MHR): 7 analysts have set the short term price target of Magnum Hunter Resources Corporation (NYSE:MHR) at $2.86. The standard deviation of short term price target has been estimated at $1.25, implying that the actual price may fluctuate by this value. The higher and the lower price estimates are $ 5 and $1 respectively.
Short of bankruptcy I will be okay, otherwise I will go down with the ship and use my investment as a write off, which is something that I have not had for almost a decade.
It looks like you totally missed my point, which was that I found ACAD at $1 and it went to $50, I found ZIOP at $2 and it went to $15 and so forth and so on, including recently I found EXEL at $2 and it is now at $6.
Speaking of your Baker Brothers who recently got killed on their XOMA position, I bought the stock in the $1's and sold it in the $6's.
Longs will have a bladder problem if they're not careful.
I have more faith in myself and my micro cap biotechnology company Diamond in the Rough stock picks than I do in the Baker Brothers portfolio.